Rucaparib Granted FDA Approval for Some Recurring Abdominal Cancers

Rucaparib Granted FDA Approval for Some Recurring Abdominal Cancers

The US FDA granted approval based on results from ARIEL3, a randomized clinical trial conducted with 561 eligible cancer patients.

Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters

Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters

Researchers hypothesize that ovarian cancer may be X-linked and associated genes may be passed from the paternal grandmother via the father's inherited genetic material.

USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women

USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women

An USPSTF updated recommendation statement for ovarian cancer screening recommends against screening for women who are asymptomatic and do not have high-risk hereditary cancer syndrome.

Investigators Examine Link Between Epithelial Ovarian Cancer Risk, Antidepressant Treatment

Investigators Examine Link Between Epithelial Ovarian Cancer Risk, Antidepressant Treatment

Researchers conducted a meta-analysis to examined possible links between antidepressant use and epithelial ovarian cancer, and links between duration and intensity of antidepressant use and risk for epithelial ovarian cancer.

Ovarian, Endometrial Cancer Risk Lower With Long-Term Oral Contraceptive Use

Ovarian, Endometrial Cancer Risk Lower With Long-Term Oral Contraceptive Use

Researchers sought to determine if a correlation was present between extended oral contraceptive use and a decreased risk of certain cancers.

Prevention, Management of Hand-Foot Syndrome With Cooling Therapy

Prevention, Management of Hand-Foot Syndrome With Cooling Therapy

Researchers explored the effectiveness of wearing frozen gloves and socks before and after treatment with PLD to prevent or manage hand-foot syndrome in patients with ovarian cancer.

Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients

1. Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and neoadjuvant chemotherapy experienced increased overall and recurrence-free survival compared to those treated with surgery and chemotherapy alone. 2. No difference in grade 3 or 4 adverse side effects were observed between HIPEC and non-HIPEC treated []

Normal tissue BRCA1 methylation associated with risk for high-grade ovarian cancer

1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). 2. BRCA1 methylation was detected in women of all ages, including newborns, suggesting that BRCA1 methylation happens at an embryonic stage. Evidence Rating Level: 3 (Average)     Study Rundown: Females with BRCA1 mutations in their germline []

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Pazopanib Plus Paclitaxel Does Not Improve Outcomes in Recurrent Ovarian Cancer

Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Ovarian Cancer Screening Potentially Cost-Effective in the United States

Ovarian Cancer Screening Potentially Cost-Effective in the United States

Multimodal screening is more expensive, but reduces ovarian cancer mortality, researchers found.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Present and Future Roles of PARP Inhibitors in Ovarian Cancer

Present and Future Roles of PARP Inhibitors in Ovarian Cancer

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

Administering niraparib to patients with recurrent ovarian cancer after CR or PR to platinum-based chemotherapy may allow patients to continuously maintain QOL during treatment, reported researchers in presentation at ESMO 2017 Congress.

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

Risk assessment study for carriers of the BRCA1/2 mutation identified the factors that influence their risk of developing breast cancer, ovarian cancer, or contralateral breast cancer.

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.

Quality of Life in Ovarian Cancer Not Diminished by Olaparib

Quality of Life in Ovarian Cancer Not Diminished by Olaparib

Change in FACT-O TOI score from baseline to 12 months did not differ significantly between maintenance olaparib and placebo.

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

A team of international researchers identified 12 new genetic variants that increase a woman's risk of developing ovarian cancer.

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.

Priority Symptoms Identified in Recurrent Ovarian Cancer

Priority Symptoms Identified in Recurrent Ovarian Cancer

There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.

Rucaparib Active in Relapsed, Platinum-sensitive Ovarian Cancer

Rucaparib Active in Relapsed, Platinum-sensitive Ovarian Cancer

Rucaparib was active with an acceptable safety profile in patients with relapsed, platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations.

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.

Rucaparib Monotherapy Approved for Advanced Ovarian Cancer

Rucaparib Monotherapy Approved for Advanced Ovarian Cancer

Rucaparib has been approved for the treatment of patients with advanced ovarian cancer who harbor a deleterious BRCA mutation.

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

Primary Cytoreductive Surgery Associated With Improved Survival in Ovarian Cancer

The benefits of primary cytoreductive surgery relative to neoadjuvant chemotherapy remain uncertain; therefore, researchers performed a retrospective data analysis to compare overall survival of surgery with that of neoadjuvant chemotherapy in advanced-stage epithelial ovarian cancer.

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

Neoadjuvant Chemotherapy Use on the Rise in Ovarian Cancer Treatment

NeoadjuvantcChemotherapy (NACT) use went up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease.

Chemotherapy During Pregnancy May Limit Baby's Fertility in Girls

Chemotherapy During Pregnancy May Limit Baby's Fertility in Girls

Etoposide was found to damage ovarian tissue in the developing fetus in a study evaluating the effect of the drug on mouse ovarian tissue grown in vitro.

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.

Socioeconomic Status Inversely Related to Risk for Ovarian Cancer in African American Women

Risk of ovarian cancer is higher in African American women with lower socioeconomic status, the opposite of trends seen in breast cancer.

Imaging and Fluorescence Technique Guides Surgical Removal of Otherwise Undetectable Ovarian Tumors

A newly created tumor-specific fluorescent molecule combined with an imaging system guided surgeons to removing additional tumors not palpable or visible without fluorescence in patients with ovarian cancer.

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

Chemotherapy Boosts Effectiveness of Immunotherapy in the Treatment of Ovarian Cancer

Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.

Exercise May Protect Against Epithelial Ovarian Cancer

Exercise May Protect Against Epithelial Ovarian Cancer

Chronic inactivity has been linked to greater risk for ovarian cancer.

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

Number of Ovarian Cancer Cases Not Treated Surgically or Not Treated at All Is Increasing

The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.

Genetic Subtypes of HLA Are Linked to Increased Overall Risk of Ovarian Cancer

Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.

Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer

Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

Study Finds Racial Disparities in Breast and Ovarian Cancer Risk Management

Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.

T Cells Have the Potential to Reverse Chemotherapy Resistance in Patients With Ovarian Cancer

A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.

No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women

Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.

Obesity Can Mask Ovarian Cancer Symptoms in African American Women

Excess abdominal fat in overweight and obese women could interfere with detection of early symptoms of ovarian cancer, and this may contribute to the higher risk of death from ovarian cancer in African American women compared with white women.

Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant

Effect of Childbirth on Risk of Ovarian Cancer Diminishes With Age, But Effect of Oral Contraceptive Use Is Constant

Prior oral contraceptive use is associated with reduced risk for ovarian cancer among women of all ages; however, risk reductions associated with childbirth wane as women age

Optimal Tumor Reduction, Platinum Sensitivity Characterize Long-term Ovarian Cancer Survival

Optimal Tumor Reduction, Platinum Sensitivity Characterize Long-term Ovarian Cancer Survival

Women who are long-term survivors of high-grade serous carcinoma (HGSC) usually have platinum-sensitive disease.

Mastectomy Increases Life Expectancy in Younger Women With Ovarian Cancer

Risk-reducing mastectomy (RRM) can increase life expectancy and be cost effective in women up to age 60 years with ovarian cancer as carriers of a BRCA mutation.

Patient-reported Outcomes Show Tamoxifen Plus OFS Worse

Patient-reported Outcomes Show Tamoxifen Plus OFS Worse

Women who received tamoxifen plus ovarian function suppression (OFS) reported worse endocrine symptoms and sexual functioning.

Hormone Replacement Therapy Improves Bone Mineral Loss After Salpingo-oophorectomy for Ovarian Cancer

In patients who undergo risk-reducing salpingo-oophorectomy, BMD screenings are underutilized in spite of the prevalence of bone mineral loss in this population. Hormone replacement therapy can address BMD loss in these women.

Progression-free and Overall Survival Better With Mutations Affecting DNA Repair Genes in Ovarian Cancer

Women with advanced ovarian cancer who had mutations affecting DNA repair genes had longer progression-free and overall survival than women without the mutations.

Current Use of Antihypertensives Linked With Slight Increase in Ovarian Cancer Risk

Current Use of Antihypertensives Linked With Slight Increase in Ovarian Cancer Risk

Current use of antihypertensive medication may be associated with a slightly increased risk for ovarian cancer.

Farletuzumab Fails to Improve Survival in Ovarian Cancer

Farletuzumab Fails to Improve Survival in Ovarian Cancer

Adding farletuzumab to carboplatin and a taxane failed to improve progression-free survival in patients with platinum-sensitive ovarian cancer.

Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?

Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?

[Journal of Gastrointestinal Oncology] This research examines the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer.

Ovarian Cancer Includes More Than One Kind of Malignancy

Ovarian Cancer Includes More Than One Kind of Malignancy

Ovarian cancer isn't a single disease, but rather a number of different malignancies, and better understanding is needed to improve prevention and treatment according to a U.S. panel.

Weekly Paclitaxel Doesn't Increase Survival in Ovarian Cancer

Weekly Paclitaxel Doesn't Increase Survival in Ovarian Cancer

Paclitaxel administered with carboplatin on a weekly basis is not associated with improved progression-free survival.

Nine Additional Inherited Gene Mutations Are Linked to Ovarian Cancer

Nine Additional Inherited Gene Mutations Are Linked to Ovarian Cancer

Among 1915 patients with ovarian cancer, almost 1 in 5 had inherited mutations in genes associated with risk of ovarian cancer. Furthermore, a total of 11 genes are now suspected of causing hereditary ovarian cancer.

Additional Genes Linked With Ovarian Cancer Risk Identified

The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.

Risk of Ovarian Cancer Predicted With Fine-tuned Test

A recent study fine-tuned the popular Simple Rules ultrasound test for ovarian cancer.

Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed

Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed

An in-depth look at the issues associated with the care reveals a need to improve how clinicians can help these women sort through their options.

Proposed Regimen for Ovarian Cancer is Aggressive, But Could Achieve a 50% Cure Rate

Proposed Regimen for Ovarian Cancer is Aggressive, But Could Achieve a 50% Cure Rate

Combining a maximal debulking strategy and intraperitoneal chemotherapy could maximize the chance of achieving a cancer-free state, as explained in a recent clinical perspective piece.

Endometrial Cancer: Minimally Invasive vs Abdominal Hysterectomy

Endometrial Cancer: Minimally Invasive vs Abdominal Hysterectomy

Minimally invasive hysterectomy does not appear to compromise long-term survival compared with abdominal hysterectomy.

Pelvic Exams Common Among Asymptomatic Older Women

Pelvic Exams Common Among Asymptomatic Older Women

Ob-gyns report external examinations are important for cancer detection and lesion identification.

NCCN Publishes New Clinical Practice Guidelines in Oncology for Vulvar Cancer

NCCN Publishes New Clinical Practice Guidelines in Oncology for Vulvar Cancer

The National Comprehensive Cancer Network (NCCN) has published its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).

Volasertib Demonstrates Antitumor Activity in Patients With Ovarian Cancer

A study compared the effectiveness of volasertib versus chemotherapy for treatment of platinum-resistant or -refractory ovarian cancer.

Familial Risk and Heritability of Cancer Is Higher Among Twins

Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.

Surgery and Chemo Combo Optimal for Elderly With Advanced Ovarian Cancer

Surgery and Chemo Combo Optimal for Elderly With Advanced Ovarian Cancer

The longest survival time was observed for primary debulking surgery coupled with chemotherapy in an optimal timeframe.

Obesity Contributes to Metastasis in Ovarian Cancer Patients

Obesity potently increases the potential for metastasis of ovarian cancer. A large number of studies have shown that higher body mass index is associated with a greater risk for ovarian cancer with worse overall survival.

Annual Screening of CA125 Protein May Reduce Ovarian Cancer Death Rate

Annual Screening of CA125 Protein May Reduce Ovarian Cancer Death Rate

Tracking levels of the CA125 protein over time may help to reduce ovarian cancer deaths by as much as 20%.

CSF1R Inhibition May Ease Debilitating Adverse Event of Ovarian Cancer

Women who have ovarian cancer often develop ascites, a buildup of fluids in the abdomen. Researchers have found that ascites can be reduced with minimal side effects through inhibition of the colony-stimulating-factor-1 receptor (CSF1R).

Breast Cancer Marker CK5 Also Marks Cisplatin-Resistant Ovarian Cancer

The protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in patients with breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.

Different Types of Ovarian Cancer Have Different Causes

The more children a woman has or whether she has undergone tubal ligation lowers her risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 NCRI Cancer Conference.

Healthy Diet May Reduce Ovarian Cancer Risk Among African Americans

Healthy Diet May Reduce Ovarian Cancer Risk Among African Americans

A healthy diet may reduce the risk for developing ovarian cancer in African American women.

Previous Oral Contaceptive Use Linked With Improved Ovarian Cancer Outcomes

Previous Oral Contaceptive Use Linked With Improved Ovarian Cancer Outcomes

Patients who develop ovarian cancer may have improved outcomes if they have prior oral contraceptive use.

Venlafaxine May Have Activity in Taxane-, Oxaliplatin-Induced Acute Neurotoxicity

Venlafaxine May Have Activity in Taxane-, Oxaliplatin-Induced Acute Neurotoxicity

Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity in patients with cancer.

Timing of Chemotherapy Initiation May Affect Advanced Ovarian Cancer Survival

Timing of Chemotherapy Initiation May Affect Advanced Ovarian Cancer Survival

Survival for women with advanced ovarian cancer may be negatively impacted when chemotherapy is initiated more than 25 days after surgery.

Hormone replacement therapy safe, may be beneficial for women treated for ovarian cancer

Hormone replacement therapy safe, may be beneficial for women treated for ovarian cancer

Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy (HRT).

Advance in photodynamic therapy offers new approach to ovarian cancer

Researchers have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.

Heart medications that target stress may prolong survival for women with ovarian cancer

Some drugs normally taken to treat heart ailments may also be beneficial for ovarian cancer.

Beta-blockers may improve survival in epithelial ovarian cancer

Beta-blockers may improve survival in epithelial ovarian cancer

Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.

Carboplatin plus paclitaxel improves quality of life in ovarian cancer

Carboplatin plus paclitaxel improves quality of life in ovarian cancer

There is no significant quality of life advantage of cisplatin plus topotecan in treatment of women with newly diagnosed ovarian cancer.

RAD51 mutations confer moderate ovarian cancer risk

RAD51 mutations confer moderate ovarian cancer risk

RAD51C and RAD51D deleterious mutations have been linked to increased risk of epithelial ovarian cancer.

Combination therapy inhibits resistance and recurrence in ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but researchers are investigating why it frequently returns after treatment.

Screening breast, ovarian cancer gene mutations other than BRCA1/2 impact management

Screening breast, ovarian cancer gene mutations other than BRCA1/2 impact management

Multigene testing for hereditary breast and/or ovarian cancer that tests is more likely to inform clinical decision-making than testing for BRCA1/2 alone.

Approximately 30 percent of patients with epithelial ovarian cancer survive long-term

Approximately 30 percent of patients with epithelial ovarian cancer survive long-term

Predictors for long-term survival include younger age, early stage, low grade, non-serous histology

Intraperitoneal chemotherapy improves ovarian cancer survival

Intraperitoneal chemotherapy improves ovarian cancer survival

Despite survival benefits, only 41 percent of suitable candidates actually receive the therapy.

Long-term survival after ovarian cancer diagnosis higher than previously thought

Long-term survival after ovarian cancer diagnosis higher than previously thought

Survival rates for ovarian cancer are higher than predicted for most women.

Chemotherapy dosages in overweight or obese patients with ovarian cancer

Overweight or obese patients with ovarian cancer are typically given lower per-pound chemotherapy doses to reduce toxic side effects, which could impact their survival chances.

Leisure sitting time associated with increased risk of cancer in women

Leisure sitting time associated with increased risk of cancer in women

Researchers have found that spending more leisure time sitting was associated with an increased risk for developing cancer in women.

Fostamatinib-paclitaxel combination may shrink ovarian cancers

Researchers have found that the experimental drug fostamatinib, combined with the chemotherapy drug paclitaxel, may overcome ovarian cancer cells' resistance to paclitaxel.

Genetic variants key to understanding origins of ovarian cancer

The discovery of three genetic variants associated with mucinous ovarian carcinomas (MOCs) offers the first evidence of genetic susceptibility in this type of ovarian cancer.

Biomarker may boost ovarian cancer response to chemotherapy

Researchers have identified a molecule that may play a central role in chemotherapy resistance in patients with the most common ovarian cancer.

Chemotherapy before surgery benefits patients with advanced ovarian cancer

Women with advanced ovarian cancer have fewer side effects and tend to have a better quality of life if given chemotherapy before surgery.

New screening technique could identify ovarian cancer in twice as many women

A new screening method utilizing protein analysis can detect ovarian cancer in twice as many women as conventional strategies, according to the latest trial results.

Biomarker may affect chemo resistance in patients with advanced ovarian cancer

Biomarker may affect chemo resistance in patients with advanced ovarian cancer

miR-506 may play a role in chemotherapy resistance in patients with ovarian cancer.

A multimodal strategy improves detection in ovarian cancer

A multimodal strategy improves detection in ovarian cancer

Screening using risk of ovarian cancer algorithm linked to increased number of screen-detected iEOCs.

Genetic testing should be accessible to all women with ovarian cancer

Women with ovarian cancer should be tested for BRCA1 and BRCA2 gene mutations, regardless of their family history.

Odds of survival improving for women with ovarian cancer

Odds of survival improving for women with ovarian cancer

Women diagnosed with ovarian cancer today are 50 percent less likely to die than they were in the 1970s.

New screening method may detect twice as many cases of ovarian cancer

New screening method may detect twice as many cases of ovarian cancer

A new screening tool can detect twice as many women with ovarian cancer as standard approaches.

Investigational personalized cellular therapy tolerated well by patients

Investigational personalized cellular therapy tolerated well by patients

An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient's own immune cells, genetically modified to target tumors.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs